An Agenus-discovered first-in-class ILT4 antibody, MK-4830, enters Phase 2
November 10, 2020 08:45 ET
|
Agenus Inc.
$10M milestone payment from Merck triggeredAgenus is eligible for up to an additional $85 million in milestones plus royalties on sales LEXINGTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Agenus...
Agenus Presents Additional Clinical Responses and Novel Biomarker Data at SITC2020
November 09, 2020 08:15 ET
|
Agenus Inc.
AGEN1181: New clinical responses and intratumoral Treg depletionAGEN1777 (TIGIT) is Fc enhanced for optimized immune performance & broader benefitAGEN2373 (anti-CD137): Clinical benefit with no...
Dr. Steven O’Day Named Agenus Chief Medical Officer
November 05, 2020 08:00 ET
|
Agenus Inc.
LEXINGTON, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and...
Agenus Doses First COVID-19 Patient with iNKT Cell Therapy
November 02, 2020 08:45 ET
|
Agenus Inc.
Allogeneic (off the shelf) iNKT cell therapy targets patients with moderate to severe COVID-19iNKT cells designed to clear SARS-CoV-2 virus while reducing harmful inflammation LEXINGTON, Mass.,...
Agenus R&D Update & Third Quarter Financial Report
October 29, 2020 07:45 ET
|
Agenus Inc.
Balstilimab rolling BLA filing and FDA review underwayCOVID-19 trial open with patients in screening for iNKT Cell TherapyNew data and clinical responses with AGEN1181 to be presented at SITC on NOV11...
Agenus to Report Third Quarter Earnings
October 20, 2020 10:34 ET
|
Agenus Inc.
LEXINGTON, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines...
Agenus to Present on Seven Novel Programs at SITC 2020
October 14, 2020 17:00 ET
|
Agenus Inc.
Clinical Responses: AGEN1181 (Fc-enhanced anti-CTLA-4) +/- balstilimabClinical Data: Zalifrelimab efficacy in refractory rare tumorsClinical & Preclinical Data: AGEN 2373 (anti-CD137)Phase 2 Data:...
Susan Hirsch Joins Agenus’ Board of Directors
October 13, 2020 08:30 ET
|
Agenus Inc.
LEXINGTON, Mass., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines...
Agenus Initiates Rolling BLA Submission of Balstilimab for Recurrent/Metastatic Cervical Cancer
September 18, 2020 08:30 ET
|
Agenus Inc.
LEXINGTON, Mass., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines...
Agenus Presents Results from Two Large Cervical Cancer Trials at ESMO
September 18, 2020 03:00 ET
|
Agenus Inc.
160 patient balstilimab (PD-1) monotherapy trial achieves response rates of 14% in all treated patients and 19% in PD-L1 positive patients155 patient balstilimab (PD-1) + zalifrelimab (CTLA-4)...